June 18, 2021
Business News

Aptinyx Reports First Quarter 2021 Financial Results and Highlights


EVANSTON, Ill.–()–Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.

“We have made excellent progress across our clinical-stage programs over the past few months,” said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. “This progress was exemplified by our positive meeting with the FDA regarding our development of NYX-783 in PTSD, and the recommencement of our Phase 2 study of NYX-458 in patients with Parkinson’s…



Click here to view the original article.

Related Posts

You might also like ...

The Alpha Blue Ocean Family Office is pleased to announce the appointment of Rajae Elantari as Head of PR & Marketing
AON Splash Image
Arkema annonce le lancement d’une nouvelle gamme innovante de grades PVDF d’origine renouvelable pour les batteries lithium-ion
Le Family Office Alpha Blue Ocean annonce la nomination de Rajae Elantari au poste de Responsable Marketing et Relations Exterieurs